Sign In
Buy IMMP
$0.407
-0.0093 (-2.24%)
At Close: Jun 03, 2026
Why Did Immutep Ltd Stock Soar Recently?
02:01am, Wednesday, 28'th Dec 2022
Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.
Immutep to Participate in Two Upcoming Investor Conferences
07:59pm, Tuesday, 01'st Nov 2022
Media Release
Immutep to Participate in Two Upcoming Investor Conferences
08:00am, Monday, 26'th Sep 2022
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapi
Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player
08:51am, Sunday, 12'th Jun 2022
Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event.
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
08:00am, Thursday, 02'nd Jun 2022
SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy t
Immutep to Present at Investor Conferences
08:00am, Friday, 20'th May 2022
SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
08:00am, Thursday, 28'th Apr 2022
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherap
Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play
12:17pm, Monday, 21'st Mar 2022
FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep's entire pipeline.
SYDNEY, AUSTRALIA, March 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new biomarker and multivariate analysis data
Immutep to Present at Healthcare Investor Conferences
08:00am, Thursday, 24'th Feb 2022
SYDNEY, AUSTRALIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022
08:00am, Friday, 18'th Feb 2022
SYDNEY, AUSTRALIA, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce new data is scheduled to be presented at ESMO
Immutep to Present at February Investor Conferences
08:00am, Monday, 31'st Jan 2022
SYDNEY, AUSTRALIA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherap
STGW, CORZ and GBIO are among after hour movers
11:02pm, Friday, 28'th Jan 2022 Seeking Alpha
Gainers: Knightscope KSCP +52%. Immutep Limited (IMMP) +4%
Immutep Limited (NASDAQ:IMMP) Short Interest Down 44.3% in November
02:20pm, Thursday, 16'th Dec 2021 Dakota Financial News
Immutep Limited (NASDAQ:IMMP) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 118,900 shares, a decrease of 44.3% from the November 15th total of 213,300 shares. Based on an average daily volume of 347,300 shares, the short-interest ratio is currently []
Immutep Advances IMP761 Manufacturing
01:00pm, Thursday, 16'th Dec 2021 Intrado Digital Media
SYDNEY, AUSTRALIA, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has signed a Manufacturing Service Agreement (MSA) with Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), to manufacture IMP761 ahead of clinical testing.
